Robert F. Kennedy Jr.'s appointment as Health Minister in Donald Trump's administration has triggered a significant decline in pharmaceutical stocks across the US and Europe, with fears of potential drug price caps impacting investor confidence. Major companies like UCB and argenx saw sharp drops, reflecting broader concerns about the future of drug pricing and regulation under Kennedy's leadership. Analysts suggest that while there are constraints on his power, the potential for reduced regulations could lead to increased mergers and acquisitions in the sector.
President-elect Donald Trump has appointed Robert F. Kennedy Jr., known for his controversial views on vaccines, to lead the Department of Health and Human Services. Kennedy, who previously ran for president as an independent, aims to address chronic diseases and reduce harmful chemicals in food. His appointment has raised concerns among public health advocates about potential negative impacts on health policies and vaccine regulation.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
